Do Dry Eye Diagnostics Change the Management of Dry Eye?

In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.

Two investigational pipeline therapies take aim at the root causes of dry eye disease

Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.

Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.

Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,

Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.

Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.

The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.